Shawn Kwatra, MD

Experts explore the challenges of multi-product topical treatment algorithms for seborrheic dermatitis (SD) and the value of once-a-day solutions in fostering adherence, improved quality of life, and overall better outcomes.

Dermatologists discuss the safety and efficacy of roflumilast for seborrheic dermatitis (SD), highlighting its tolerability across backgrounds and age groups, safety in pediatric care, and the unmet need it fulfills.

Dermatologists discuss a groundbreaking agent, roflumilast, filling a void in seborrheic dermatitis (SD) treatment. These experts highlight patient-reported response to this novel treatment and their own experiences in clinical trials with this drug.

Dermatologists discuss diverse patient presentations and effective treatments for seborrheic dermatitis (SD), addressing over-the-counter product challenges, immune signatures, and treatment nuances in pediatric care.

Experts shed light on the challenges of seborrheic dermatitis treatment, emphasizing the historical lack of treatment options and importance of patient education.

Dermatologists discuss the profound impact of seborrheic dermatitis on an individual’s quality of life, discussing self-reported effects on self-esteem, social interactions, and career trajectories.

Dermatologists discuss differentiating seborrheic dermatitis from conditions like psoriasis, eczema, and lupus, highlighting similarities and differences with other skin conditions.

Dermatologists introduce this series providing and overview of seborrheic dermatitis (SD), highlighting common causes, contributing factors, and the various ways it may present in different patient populations.

Shawn Kwatra, MD, and Sarina B. Elmariah, MD, PhD, share final pearls of wisdom for other physicians taking care of patients with prurigo nodularis (PN).

Experts in dermatology discuss unmet needs in prurigo nodularis (PN) and the importance of addressing those needs for disease management.

Drs Raj Chovatiya, Shawn Kwatra, and Sarina B. Elmariah review exciting new therapies in the treatment landscape of PN.

Experts in dermatology share thoughts on the need for additional investigative research of prurigo nodularis in order to better treat patients.

Raj Chovatiya, MD, PhD; Shawn Kwatra, MD; and Sarina B. Elmariah, MD, PhD, discuss potential challenges to the adoption of dupilumab in the treatment of PN.

Experts in dermatology discuss ideal candidates for dupilumab.

Drs Raj Chovatiya, Shawn Kwatra, and Sarina B. Elmariah review PRIME and PRIME 2 phase 3 studies of dupilumab for treatment of PN.

Raj Chovatiya, MD, PhD; Shawn Kwatra, MD; and Sarina B. Elmariah, MD, PhD, discuss a newly approved drug, dupilumab, for the treatment of PN.

Raj Chovatiya, MD, PhD, reviews the limitations of topical treatments when managing PN.

Sarina B. Elmariah, MD, PhD, talks about less commonly used treatments for patients with prurigo nodularis (PN).

Raj Chovatiya, MD, PhD; Shawn Kwatra, MD; and Sarina B. Elmariah, MD, PhD; provide an overview of therapies currently available for treating PN.

Raj Chovatiya, MD, PhD; Shawn Kwatra, MD; and Sarina B. Elmariah, MD, PhD; share guideline resources that physicians turn to when treating PN.

Experts in dermatology discuss treatment goals for PN and how they can differ based on severity of itching and nodules.

Raj Chovatiya, MD, PhD; Shawn Kwatra, MD; and Sarina B. Elmariah, MD, PhD, share the importance of having multiple health care providers across the disciplines when diagnosing and treating prurigo nodularis (PN).

Experts in dermatology examine a patient’s road to diagnosis of prurigo nodularis (PN), focusing on the symptoms that bring them to the initial specialist visit.

Raj Chovatiya, MD, PhD; Shawn Kwatra, MD; and Sarina B. Elmariah, MD, PhD, discuss the pathophysiology on PN and the role of type 1 inflammation in the disease.

Raj Chovatiya, MD, PhD; Shawn Kwatra, MD; and Sarina B. Elmariah, MD, PhD, provide an overview of prurigo nodularis (PN), its prevalence, and how it is a unique disease state to be differentiated from other disorders.